2020
17
September
2020
|
08:57
Europe/Amsterdam
Outcomes of the BIO4AMB trial presented at the CIRSE 2020 Summit demonstrated that ambulatory treatment with 4‑French (4F) devices is a valid and safe option for endovascular treatment of lower extremity peripheral artery disease (PAD). The 4F compa...
Read more